News
Friday, 25 August 2017
update
Viewray: Compelling Early Pancreatic Cancer Data with ViewRay’s MRIdian System Presented at ESTRO 36
Presentations Also Highlighted Speed and Benefit of On-Table Adaptive Therapy in Routine Clinical Use
May 15, 2017
CLEVELAND, May 15, 2017 — ViewRay, Inc. (Nasdaq: VRAY) announced today highlights from ESTRO 36, the annual meeting of the European Society for Radiotherapy and Oncology, which featured broad clinical experience with the company’s MRIdian System, including compelling early data on its use in pancreatic cancer.
Read more
Monday, 21 August 2017
update
Viewray: Henry Ford Treats World’s First Patient Using New MRI-Guided Radiation Therapy that Simultaneously Tracks, Treats Tumor
The Henry Ford Cancer Institute has treated the world’s first cancer patient today with an advanced radiation therapy that uses an FDA-cleared real-time magnetic resonance imaging and linear accelerator delivery for more precise and accurate radiation treatment.
Read more